Cynapsus Therapeutics Inc Stock

Stocks

Delayed Toronto S.E.			5-day change	1st Jan Change
- ^CAD	-.--%		+0.21%	-

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT

06-03	HyProMag Ltd is 100% Owned by Maginito Ltd, Which is Owned on a 79.4%/20.6% Basis by Mkango Resources and CoTec	MT
06-03	HyProMag USA LLC is Owned 50:50 by CoTec and HyProMag Limited	MT
06-03	CoTec JV, HyProMag USA, to Commence Preparatory Work for Project Execution Phase at Dallas-Fort Worth Texas Hub	MT
05-20	CoTec Releases Updated Mineral Resource and "Positive" PEA for Lac Jeannine Iron Tailings Project; Lost Near 10% on Tuesday	MT
24-03-11	Mkango and CoTec Brief: Mkango Subsidiary, Maginito, And CoTec Appointed Lead Engineers BBA And Pegasus To Complete Feasibility Study for HyProMag USA	MT
24-01-29	CoTec Holdings Outlines Key Targets For 2024	MT
24-01-03	Mkango Surges Near 12% As Forms HyProMag Joint Venture In US With CoTec	MT
23-10-10	Mkango Surges 11% As Says To Commence Feasibility Study For Proposed US Operation With CoTec	MT
23-10-10	Mkango, CoTec To Commence Feasibility Study For Proposed US Operation	MT
23-10-02	CoTec Completed Conversion of 2 Million Pounds Mkango Loan Note to Double Equity Position in Maginito to 20.6%	MT
23-09-14	Mkango Down Near 3% As Agrees To Form US Joint Venture With CoTec Holdings	MT
23-09-14	CoTec Holdings, Mkango To Form US Joint Venture	MT
23-06-30	Kings Chapel Increases Stake In CoTec Holdings	MT

05-06	COPPER INTELLIGENCE TO FORM AN EARLY-STAGE EXPLORATION JOINT VENTURE WITH COTEC TO TARGET PROCESSING HISTORICAL COPPER TAILINGS OPPORTUNITIES IN THE DEMOCRATIC REPUBLIC OF CONGO	PR
16-08-31	Cynapsus Therapeutics : Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics	PU
16-08-29	Cynapsus Therapeutics : Receives FDA Fast Track Designation for APL-130277 for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL
16-08-15	Cynapsus Therapeutics : Announces Positive Opinion from Data and Safety Monitoring Board on Phase 3 Parkinson's Disease Clinical Study Allowing for At-Home Titration	GL
16-08-12	Cynapsus Therapeutics : Announces Publication in the Journal Movement Disorders of Data for the Treatment of OFF Episodes in Patients with Parkinson's Disease	GL

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CYNAPSUS THERAPEUTICS INC	-.--%	+0.21%	-	-	0
WUXI APPTEC CO., LTD.	+2.41%	-6.33%	+43.43%	+71.02%	63.29B
ARGENX SE	-0.15%	+7.50%	+11.01%	+73.48%	54.89B
LONZA GROUP AG	+0.57%	+4.60%	+10.07%	+92.86%	53.28B
IQVIA HOLDINGS INC.	+0.38%	+4.55%	+26.89%	+51.90%	45.81B
BEONE MEDICINES AG	-1.18%	+2.49%	+22.00%	+124.17%	43.46B
REVOLUTION MEDICINES, INC.	-0.39%	+5.43%	+251.10%	+922.23%	40.23B
CELLTRION, INC.	+0.05%	+6.75%	+14.48%	+56.75%	33.45B
WUXI BIOLOGICS (CAYMAN) INC.	+1.19%	-5.84%	+27.86%	-0.65%	23.7B
GENMAB A/S	-0.38%	+5.68%	+36.43%	+27.54%	23.76B
Average	+0.29%	+0.33%	+49.25%	+157.70%	42.43B
Weighted average by Cap.	+0.42%	+0.55%	+47.63%	+159.44%

Employees

Sector